ORIC Pharmaceuticals Reports Inducement Grants

Biotech firm grants stock options and restricted stock units to new employee

Apr. 6, 2026 at 3:49am

Got story updates? Submit your updates here. ›

A photorealistic studio still-life featuring a polished metal syringe, a glass vial, and a pill capsule arranged on a clean white background, conceptually representing the tools and materials of pharmaceutical research and development.Precision instruments and materials symbolize the meticulous research and development efforts behind ORIC's clinical-stage oncology pipeline.San Diego Today

ORIC Pharmaceuticals, a clinical-stage oncology company, announced that it has granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee who joined the company in March 2026. The inducement grants were approved by ORIC's Compensation Committee and granted as a material inducement to employment.

Why it matters

The announcement of these inducement grants provides insight into ORIC's efforts to attract and retain top talent as it continues to advance its clinical-stage oncology pipeline. Offering competitive equity-based compensation is a common practice in the biotech industry to incentivize new hires and align their interests with those of the company and its shareholders.

The details

The stock options have an exercise price equal to the closing price of ORIC's common stock on the grant date. Twenty-five percent of the shares subject to the stock options will vest on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the following three years. One-third of the restricted stock units will vest on each of the first three anniversaries of the grant date.

  • The grants were made on April 1, 2026.
  • The new employee joined ORIC in March 2026.

The players

ORIC Pharmaceuticals, Inc.

A clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance.

Dominic Piscitelli

Chief Financial Officer of ORIC Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date.”

— Dominic Piscitelli, Chief Financial Officer

What’s next

ORIC will continue to monitor the vesting of the inducement grants and provide updates on the progress of its clinical-stage oncology pipeline.

The takeaway

The announcement of these inducement grants highlights ORIC's commitment to attracting top talent as it works to advance its oncology treatments and overcome resistance in cancer. Equity-based compensation is a common tool used by biotech companies to incentivize and retain key employees.